News Image

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

By Mill Chart

Last update: Feb 28, 2024

Here's NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) for you, a growth stock our stock screener believes is undervalued. NASDAQ:NBIX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.

Exploring NASDAQ:NBIX's Growth

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:NBIX has achieved a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 58.17% over the past year.
  • NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 70.09% yearly.
  • The Revenue has grown by 26.76% in the past year. This is a very strong growth!
  • The Revenue has been growing by 33.13% on average over the past years. This is a very strong growth!
  • The Earnings Per Share is expected to grow by 42.64% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 13.87% on average over the next years. This is quite good.

Assessing Valuation Metrics for NASDAQ:NBIX

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:NBIX, the assigned 7 reflects its valuation:

  • 94.75% of the companies in the same industry are more expensive than NBIX, based on the Price/Earnings ratio.
  • Based on the Price/Forward Earnings ratio, NBIX is valued cheaper than 95.42% of the companies in the same industry.
  • NBIX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.75% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 95.59% of the companies are valued more expensively.
  • NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NBIX's earnings are expected to grow with 62.72% in the coming years.

A Closer Look at Health for NASDAQ:NBIX

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:NBIX, the assigned 7 for health provides valuable insights:

  • An Altman-Z score of 9.13 indicates that NBIX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of NBIX (9.13) is better than 82.88% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.45 indicates that NBIX has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.40 indicates that NBIX has no problem at all paying its short term obligations.

Assessing Profitability for NASDAQ:NBIX

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:NBIX scores a 9 out of 10:

  • The Return On Assets of NBIX (7.68%) is better than 96.61% of its industry peers.
  • The Return On Equity of NBIX (11.19%) is better than 96.27% of its industry peers.
  • NBIX has a better Return On Invested Capital (11.21%) than 96.78% of its industry peers.
  • The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(11.21%), indicating increased profibility in the last year.
  • NBIX's Profit Margin of 13.23% is amongst the best of the industry. NBIX outperforms 96.61% of its industry peers.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • NBIX's Operating Margin of 20.92% is amongst the best of the industry. NBIX outperforms 97.12% of its industry peers.
  • In the last couple of years the Operating Margin of NBIX has grown nicely.
  • NBIX has a better Gross Margin (97.90%) than 97.63% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of NBIX

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/19/2024, 3:07:16 PM)

After market: 132 0 (0%)

132

-0.54 (-0.41%)

NBIX News

News Image3 days ago - Sentia Medical Sciences, Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
News Image8 days ago - ChartmillWhy NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image9 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

News Image9 days ago - ChartmillFor those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

News Image14 days ago - ChartmillDon't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.

In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals.

News Image16 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

News Image22 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...

News Imagea month ago - Investor's Business DailyS&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

News Imagea month ago - Investor's Business DailyAI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

Three of the featured stocks are closing in on record highs.

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences to Participate at Virtual Investor Conferences in March

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming virtual investor conferences in March. Eiry Roberts, Chief Medical...

NBIX Links
Follow us for more